A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of BG00012 When Given With Methotrexate to Subjects With Active RA Who Have Had an Inadequate Response to Conventional Disease-Modifying Anti-rheumatic Drug Therapy

The purpose of this study is to investigate whether the drug BG00012 can improve the symptoms
of rheumatoid arthritis (RA) in patients who are already taking methotrexate for RA, but who
still suffer symptoms of RA. The purpose is also to ensure that the combination of
methotrexate is safe for patients to take and that any side effects are acceptable to
patients with RA.